Sharp-Header

Sharp-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Alebund Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Food & Nutrition Conference & Expo

Participation Not Confirmed

Update your Virtual Booth

Alebund Pharmaceuticals Raises $60 million in Series B Financing Round

Lead Product(s): AP-301

Therapeutic Area: Nephrology Product Name: AP-301

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Quan Capital

Deal Size: $60 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 09, 2021

Details:

Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.